Key facts
- It has raised $42.3M; the latest was Early Stage VC ($13.7M) in Jan 2025.
- Notable investors include CICC Capital, Yijing Capital, VI Ventures, Elikon Venture, Gaorong Ventures — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Biovision Biomedical Technology
- ·The full record, as it builds
Funding rounds
No funding rounds for Biovision Biomedical Technology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Biovision Biomedical Technology
Operator of a clinical-stage biopharmaceutical company intended to focus on the discovery, development, and commercialization of novel targeted radiopharmaceuticals to address significant unmet medical needs. The company's proprietary technology platform for selecting targeting ligands, radiation drug-conjugate, and translational medicine for its drug R&D programs, enabling patients with advanced treatments.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2021
- Employees
- 25
- Website
- bivisionpharma.com/
- Ownership
- Privately Held (backing)
Biovision Biomedical Technology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Biovision Biomedical Technology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Biovision Biomedical Technology in its N-PORT filings yet. We sweep new filings monthly.